Genfit SANASDAQ:GNFT
- LAST PRICE3.3500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.2100/ 5
- Ask / Lots3.2500/ 27
- Open / Previous Close0.0000 / 3.3500
- Day Range---
- 52 Week Range
- Volume585
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GNFT |
|---|---|---|
| 09:32 ET | 202 | 3.35 |
| 09:39 ET | 100 | 3.3505 |
| 09:54 ET | 100 | 3.35 |
| 10:14 ET | 100 | 3.37 |
| 10:19 ET | 400 | 3.35 |
| 10:24 ET | 1408 | 3.35 |
| 10:33 ET | 100 | 3.35 |
| 11:02 ET | 100 | 3.36 |
| 11:04 ET | 100 | 3.35 |
| 11:15 ET | 400 | 3.34 |
| 11:42 ET | 500 | 3.3 |
| 11:45 ET | 500 | 3.39 |
| 11:47 ET | 500 | 3.31 |
| 11:56 ET | 100 | 3.3235 |
| 03:59 ET | 300 | 3.35 |
Sep 21, 2023
DJ Genfit Price Target Maintained With a $11.00/Share by HC Wainwright & Co., from 6:42AM ET on Thursday Sep 21, 2023 by Dow Jones
6:42AM ET on Thursday Sep 21, 2023 by Dow Jones
Sep 20, 2023
GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update, from 4:10PM ET on Wednesday Sep 20, 2023 by Dow Jones
4:10PM ET on Wednesday Sep 20, 2023 by Dow Jones
Sep 5, 2023
GENFIT to Participate in Upcoming Investor Conferences, from 4:10PM ET on Tuesday Sep 05, 2023 by Dow Jones
4:10PM ET on Tuesday Sep 05, 2023 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Genfit SA | 168.4M | -6.6x | --- |
Adaptimmune Therapeutics PLC | 177.0M | -1.4x | --- |
Mersana Therapeutics Inc | 153.0M | -0.6x | --- |
Carisma Therapeutics Inc | 158.7M | -3.5x | --- |
Zomedica Corp | 163.7M | -8.4x | --- |
Ikena Oncology Inc | 192.9M | -2.7x | --- |
Company Information
Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
Contact Information
- Headquarters
- Parc Eurasante 885 avenue Eugene AvineeLOOS, France 59120
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Jean-Francois Mouney
- Independent Vice Chairman of the Board
- Xavier Guille Des Buttes
- Chief Executive Officer
- Pascal Prigent
- Chief Financial Officer
- Thomas Baetz
- Chief Operating Officer
- Pascal Caisey
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $168.4M |
|---|---|
Revenue (TTM) | $28.3M |
Shares Outstanding | 49.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.13 |
EPS | $-0.51 |
Book Value | $2.02 |
P/E Ratio | -6.6x |
Price/Sales (TTM) | 5.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -102.72% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
